Daniel A. Ermann, MD

Lymphoma/CLL Specialist @UofUHealth @huntsmancancer | My opinions are my own |

[Daniel A. Ermann, MD @ErmannMD]

Had an incredible time filming and participating in this fun discussion with some amazing CLL docs. Check it out!

[OncLive.com @OncLive]

How is the CLL treatment landscape shifting? Join experts to explore BTK and BCL2 inhibitor sequencing, MRD-guided strategies, and the role of pirtobrutinib.

Watch the full series: https://t.co/8HpC4VblTt

@ErmannMD @UofUHealth @huntsmancancer @JavierPinillaMD @MoffittNews @mshadman @fredhutch

[CU Anschutz Lymphoma Program @CULymphoma]

Dr. @StevenBairMD @CULymphoma contributed to a multicenter study published in @Haematologica about real-world outcomes of lonca in R/R DLBCL. https://t.co/CM4F2Ns1be #lymsm

[Ajay Major, MD, MBA @majorajay]

RW lonca R/R DLBCL outcomes:
- 187 pts, 17% bulky, 22% HGBL, 60% prior CAR
- ORR 32%, CR 14% (woof), no diff in outcomes if prior CAR
- mEFS 2.1 mos, mOS 4.6 mos
Dismal outcomes outside of trial setting. #lymsm
https://t.co/FpNSsOvsHa

[Ajay Major, MD, MBA @majorajay]

Mosun-pola-CHP vs pola-R-CHP 1L DLBCL
- 62 pts
- mosun arm: CR 73%, 2-yr PFS 71%
- pola-R-CHP: CR 77%, 2-yr PFS 82%
- more tx d/c in mosun arm
No sig benefit of mosun-pola-CHP. #lymsm
https://t.co/LIiwTNQI7I

[Binaytara @binaytara]

We are excited to have @ErmannMD from @UofUHealth @huntsmancancer, @poh_christina from @fredhutch @UWMedicine and @TravisWiliamsDO from @stlukeshealth talking about #lymphoma at #BTFHemBreast25 in Boise! Join us: https://t.co/i1EG9ddP2z #MedTwitter #MedX #MedEd

[Ajay Major, MD, MBA @majorajay]

Pola outcomes by Hans COO @Eddie_Cliff @dgermain21 #ASH24
- >700 pts in 1L & R/R cohorts
- non-GC ORR/CR significantly better in R/R (60% vs 36%), but not 1L cohort
- non-GCC PFS (not OS) better in R/R, not 1L
- PFS better for non-GC if pola used after (not before) CAR
1/ #lymsm

[calliecoombs @calliecoombsmd]

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfenske #ASH24

[CU Anschutz Lymphoma Program @CULymphoma]

Our @CULymphoma faculty Dr. @StevenBairMD contributed to a multicenter real-world study of loncastuximab in R/R DLBCL in @Haematologica. Outcomes were inferior to those described in clinical trials, with median EFS and OS of 2.1 and 4.6 months. #lymsm
https://t.co/CM4F2NrtlG

[Ajay Major, MD, MBA @majorajay]

Golcadomide (CELMoD)+RCHOP 1L LBCL @Lymphoma_Doc #ASH24:
- randomized 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm

[NEJM @NEJM]

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: https://t.co/BdiBCue4dt

[Binaytara @binaytara]

Congratulations to the 2024 Young Hematology Scholar Awardees! 🏆🩸Thank you for sharing your groundbreaking work and presenting at the #HemeSummit24 this weekend in Nashville! @AkritiC54828 @EmperorBlackMD @FahminB_MDPhD @LopedotePaolo @HannahGoulart @KLChohan @MDAndersonNews @MCIStrong @UICancerCenter @DukeMedSchool @COH_RadOnc @UofUHealth @NorthwesternMed
Read more: https://t.co/zWqUBPb3eU
#YoungHematologyScholars #HemOnc #Oncology #cancer #medx #meded #OncoDaily

[Adam Kittai @AdamKittai]

Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting.
@TischCancer
@IcahnMountSinai

https://t.co/oIXwP0Rbao

[Oncology News Central @OncNewsCentral]

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. https://t.co/AlXjAjsMws #CLLSM @ErmannMD @UofUHealth @huntsmancancer

[Oncology News Central @OncNewsCentral]

New frontiers in r/r CLL: Dr. Daniel Ermann explores pirtobrutinib and CAR-T therapy. Key points on efficacy, toxicity, and patient selection. How will these options impact your treatment decisions? https://t.co/AlXjAjsMws #CLLSM @ErmannMD @UofUHealth @huntsmancancer

[Oncology News Central @OncNewsCentral]

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. https://t.co/AlXjAjsMws #CLLSM @ErmannMD @UofUHealth @huntsmancancer

[Toby Eyre @tobyeyre82]

Important new #CLL news

PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL.

https://t.co/tRSPVlDmJY

[Leukemia Research Foundation @LeukemiaRF]

Healthcare providers: Our partner, Patient Empowerment Network (PEN), is hosting a webinar addressing optimizing CLL care, with @ChangMDPhD of Emory Healthcare and @ErmannMD of Huntsman Cancer Institute, on Aug. 13 at 1pm ET. Learn more: https://t.co/X451iHkA0C

[Adam Kittai @AdamKittai]

Check out @ErmannMD and my new article @ASCO, #ASCODailyNews on Treatment of Richter Transformation. @TischCancer
-Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach https://t.co/cyus6i7nSd

[Toby Eyre @tobyeyre82]

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma https://t.co/z9pnyrF6zN

[CLL Society Inc. @CllSociety]

Data on patient outcomes for individuals with #CLL who are >80 is limited due to their underrepresentation in clinical trials. This study used information from the Mayo Clinic CLL Database to analyze how this population responds to treatment for CLL. https://t.co/rCAypnn2JB